AUTHORS
Rebecca Sarah Maynard, MSc, PhD, Vassilena Sharlandjieva, DPhil2, Pauline Schneider3, Alastair Smith, PhD4, Shanissa Meah5, Tom Wilson6, Simone Riva7, Jim Hughes, DPhil8, Anindita Roy, MRCPCH FRCPath PhD9, Ronald Stam, PhD10, Thomas A Milne, PhD11
AFFILIATIONS
1 University of Oxford, Oxford, England, United Kingdom
2 University of Oxford, Oxford, England, United Kingdom
3 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
4 University of Oxford, Oxford, England, United Kingdom
5 University of Oxford, Oxford, England, United Kingdom
6 University of Oxford, Oxford, England, United Kingdom
7 University of Oxford, Oxford, England, United Kingdom
8 University of Oxford, Oxford, England, United Kingdom
9 University of Oxford, Oxford, England, United Kingdom
10 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
11 University of Oxford, Oxford, England, United Kingdom
ABSTRACT
Background. KMT2A-rearranged (KMT2Ar) paediatric B-cell acute lymphoblastic leukaemia (B-ALL) is an aggressive leukaemia subtype associated with poor prognosis and high rates of relapse despite intensive treatment (1). Disruption of the Menin–KMT2A interaction has emerged as an effective therapeutic strategy, with the Menin inhibitor Revumenib demonstrating encouraging clinical activity in patients with relapsed or refractory KMT2Ar acute leukaemia’s and gaining regulatory approval in some settings (2, 3). However, acquired resistance is an emerging clinical challenge (4). Understanding the molecular mechanisms causing resistance is essential for improving therapeutic responses and identifying potential strategies to overcome treatment failure.
Results. To investigate the inhibitor resistance, the KMT2Ar acute lymphoblastic leukaemia (ALL) cell line SEM was cultured under prolonged exposure to the Menin inhibitor Revumenib, generating two independently derived resistant cell lines following dose escalation to 1 µM and 10 µM. Both resistant populations acquired MEN1 M321T mutation and exhibited robust resistance to Menin inhibition, with an IC50 of 6.27mM and 7.37mM in the resistant lines, compared to 4.68nM in the control. As well as a 145% increase in colony forming potential at 25nM (P = 0.0027). Conversely, there was a 56.5% reduction in colony forming potential in the resistant line compared to control (P = 0.0272), and in vivo xenograft models showed that the resistant cell line had significantly delayed engraftment with median overall survival of 57.0 days vs 37.0 days in the wildtype engrafted mice (HR 3.333, 95% CL 0.4920 to 22.58; log-rank P = 0.0143).
To investigate the molecular mechanisms behind the reduced leukemic potential we examined transcriptional change via RNA-seq. Resistant cells downregulated genes associated with cell-cycle progression, including CDK6, consistent with the impaired proliferative ability seen in vivo and in vitro. In addition, resistant cells exhibited reduced expression of canonical Menin/KMT2A target genes, including HOXA9, HOXA7 and MEIS1 (2), alongside altered expression of lineage-associated transcription factors, suggesting selective transcriptional rewiring rather than complete disruption of Menin-dependent gene regulation. Resistant cells also upregulated stress-response and niche-associated regulators including FOXO1/3, CXCR4, ITGA6 and ITGB1, together with increased CDKN2A and CDKN1A. In the absence of induction of several canonical senescence-associated genes, these findings suggest acquisition of a stress-adapted transcriptional state with features of an impaired senescence programme, similar to that recently described in Menin inhibitor-resistant KMT2Ar leukaemia (5). To determine how inhibitor resistance alters Menin-dependent chromatin regulation, CUT&Tag and ChIPmentation were performed for Menin, MLL, ENL, LEDGF, H3K27ac, H3K27me3 and H3K79me3. We see decreased complex binding at the CDK6 locus, whereas other loci remain the same as wildtype, such as RUNX1, where gene expression remain unaltered. We hypothesise that the mutation results in a less active complex as evidenced by H3K79me3 deposition at specific loci. These findings suggest selective rewiring of Menin-dependent transcriptional programmes rather than global disruption of complex recruitment.
Conclusion. Together, these findings indicate that acquired Menin inhibitor resistance in KMT2Ar ALL is associated with transcriptional and epigenetic adaptation, resulting in reduced proliferative fitness yet maintaining leukemic potential. Loss of the canonical HOXA9/MEIS1 transcriptional programme, together with acquisition of a stress-adapted and an impaired senescence-like transcriptional response, suggests that resistance may involve selective cellular reprogramming rather than restoration of Menin-dependent signalling. Understanding how these alterations in chromatin binding and cell-state transitions support survival under therapeutic pressure may reveal novel therapeutic strategies to understand therapy resistance.
Górecki M, et al. Biomedicines. 2023;11(3).
Krivtsov AV, et al. Cancer Cell. 2019;36(6):660-73.e11.
Issa GC, et al. J Clin Oncol. 2025;43(1):75-84.
Perner F, et al. Nature. 2023;615(7954):913-9.
Mahdavi L, et al. Exp Hematol. 2026;153:105268.
DISCLOSURES
Rebecca Sarah Maynard, MSc, PhD: No relevant conflicts of interest to declare.